Hepatitis C associated membranoproliferative glomerulonephritis treated with directly acting antivirals for hepatitis C
نویسندگان
چکیده
Hepatitis C virus (HCV) infection affects kidneys with different histopathological patterns on kidney biopsy, which commonly include membranoproliferative glomerulonephritis (MPGN) pattern mixed cryoglobulinemia (CG), thrombotic microangiopathy, membranous nephropathy and small to medium vessel vasculitis. Type 1 MPGN associated type II CG is the most common glomerulopathy hepatitis infection. Treatment of these glomerulopathies cryoglobulinemic renal disease HCV includes antiviral therapy for HCV, B-cell depletion prevention immune complexes cryoglobulins or nonspecific immunosuppressive therapy. We describe a patient who presented us cryogloblinemia detectable RNA, recovered completely directly acting agents (DAA) alone without immunosuppression.
منابع مشابه
Directly acting antivirals against hepatitis C virus.
The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide. Paradoxically, hepatitis C is the only human chronic viral disease that can be cured, as all other pathogenic viruses infecting humans either display self-limited courses or establish non-eradicable pe...
متن کاملRituximab therapy for hepatitis C virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis
Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV-related vasculitis and may evade the need for dialysis as in our patient.
متن کاملRisk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. However, hepatitis B virus (HBV) reactivation has been reported in HCV/HBV co-infected patients. H...
متن کاملNew directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Recent advances in the development of agents that act specifically to inhibit hepatitis C virus (HCV) are set to fundamentally change the way that patients will be treated. New directly acting anti-HCV agents such as protease and polymerase inhibitors will initially be added to standard of care with pegylated interferon-alpha and ribavirin. However, future therapy is likely to constitute combin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Advances in Medicine
سال: 2022
ISSN: ['2349-3925', '2349-3933']
DOI: https://doi.org/10.18203/2349-3933.ijam20222405